Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167952 | 0.90 | TSHR (0.50) | TSHRHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4167051 | 0.90 | PTGDR2 (0.54) | TSHRHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4169745 | 0.87 | TSHR (0.54) | TSHRHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4261411 | 0.82 | AKR1B1 (0.38) | TSHRHTTSMN1; SMN2ALDH1A1ADAMTS5 | |
| SCHEMBL4165983 | 0.82 | MAPT (0.44) | TSHRHTTSMN1; SMN2ALDH1A1PTGDR2 | |
| SCHEMBL4259885 | 0.78 | ADAMTS5 (0.52) | HTTSMN1; SMN2ALDH1A1TDP1ADAMTS5 | |
| SCHEMBL4164579 | 0.78 | TSHR (0.47) | TSHRHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4168475 | 0.78 | ADAMTS5 (0.38) | TSHRHTTSMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL4258971 | 0.77 | TP53 (0.45) | SMN1; SMN2ALDH1A1PTGDR2ADAMTS5AKR1B1 | |
| SCHEMBL4159534 | 0.77 | ADAMTS5 (0.42) | SMN1; SMN2ALDH1A1ADAMTS5AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | TSHR 401/4885HTT 2355/4885SMN1; SMN2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.